BofA raised the firm’s price target on Edwards Lifesciences (EW) to $82 from $75 and keeps a Neutral rating on the shares. While stating that the path forward “seems more favorable” post the company’s analyst day and new guidance, the firm reiterates a Neutral rating as it thinks that the PE multiple already reflects Edwards’ growth outlook. However, as long as Edwards can execute against this new guidance, the firm thinks that “interest will build over 2025 into moderate data at TCT 2026,” the analyst added.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on EW:
- Edwards Lifesciences price target raised to $75 from $70 at TD Cowen
- Edwards Lifesciences price target raised to $68 from $63 at Canaccord
- Early notable gainers among liquid option names on December 4th
- Edwards Lifesciences sees FY25 adjusted EPS $2.40-$2.50, consensus $2.47
- Edwards Lifesciences backs FY24 constant currency sales growth of 8%-10%
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
